Last reviewed · How we verify
Thrombosis in Heparin Induced Thrombocytopenia — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Argatroban | ARGATROBAN | Hikma Pharm Co Ltd | Anti-coagulant [EPC] | Prothrombin | 2000-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Thrombosis in Heparin Induced Thrombocytopenia
- Hikma Pharm Co Ltd · 1 drug in Thrombosis in Heparin Induced Thrombocytopenia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Thrombosis in Heparin Induced Thrombocytopenia:
- Thrombosis in Heparin Induced Thrombocytopenia treatment updates — RSS
- Thrombosis in Heparin Induced Thrombocytopenia treatment updates — Atom
- Thrombosis in Heparin Induced Thrombocytopenia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Thrombosis in Heparin Induced Thrombocytopenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/thrombosis-in-heparin-induced-thrombocytopenia. Accessed 2026-06-10.
Related
- Thrombosis in Heparin Induced Thrombocytopenia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing